BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 34140271)

  • 1. Neonatal cystic fibrosis screening: Analysis and differences in immunoreactive trypsin levels in newborns with a positive screen.
    Arrudi-Moreno M; García-Romero R; Samper-Villagrasa P; Sánchez-Malo MJ; Martin-de-Vicente C
    An Pediatr (Engl Ed); 2021 Jul; 95(1):11-17. PubMed ID: 34140271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunoreactive trypsinogen in healthy newborns and infants with cystic fibrosis.
    Fingerhut R; Rueegg CS; Imahorn O; Pedersen ESL; Kuehni CE; Gallati S; Regamey N; Barben J
    Arch Dis Child Fetal Neonatal Ed; 2023 Mar; 108(2):176-181. PubMed ID: 36351789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunoreactive trypsinogen levels in newborn screened infants with an inconclusive diagnosis of cystic fibrosis.
    Ooi CY; Sutherland R; Castellani C; Keenan K; Boland M; Reisman J; Bjornson C; Chilvers MA; van Wylick R; Kent S; Price A; Mateos-Corral D; Hughes D; Solomon M; Zuberbuhler P; Brusky J; Durie PR; Ratjen F; Gonska T
    BMC Pediatr; 2019 Oct; 19(1):369. PubMed ID: 31640630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cystic fibrosis newborn screening in Denmark: Experience from the first 2 years.
    Skov M; Baekvad-Hansen M; Hougaard DM; Skogstrand K; Lund AM; Pressler T; Olesen HV; Duno M
    Pediatr Pulmonol; 2020 Feb; 55(2):549-555. PubMed ID: 31682332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of DNA analysis in a population-screening program for neonatal diagnosis of cystic fibrosis (CF): comparison of screening protocols.
    Gregg RG; Wilfond BS; Farrell PM; Laxova A; Hassemer D; Mischler EH
    Am J Hum Genet; 1993 Mar; 52(3):616-26. PubMed ID: 7680526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenotype of children with inconclusive cystic fibrosis diagnosis after newborn screening.
    Munck A; Bourmaud A; Bellon G; Picq P; Farrell PM;
    Pediatr Pulmonol; 2020 Apr; 55(4):918-928. PubMed ID: 31916691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening for cystic fibrosis in New York State: considerations for algorithm improvements.
    Kay DM; Maloney B; Hamel R; Pearce M; DeMartino L; McMahon R; McGrath E; Krein L; Vogel B; Saavedra-Matiz CA; Caggana M; Tavakoli NP
    Eur J Pediatr; 2016 Feb; 175(2):181-93. PubMed ID: 26293390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population-based newborn screening for genetic disorders when multiple mutation DNA testing is incorporated: a cystic fibrosis newborn screening model demonstrating increased sensitivity but more carrier detections.
    Comeau AM; Parad RB; Dorkin HL; Dovey M; Gerstle R; Haver K; Lapey A; O'Sullivan BP; Waltz DA; Zwerdling RG; Eaton RB
    Pediatrics; 2004 Jun; 113(6):1573-81. PubMed ID: 15173476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnosing cystic fibrosis in newborn screening in Poland - 15 years of experience.
    Sands D; Zybert K; Mierzejewska E; Ołtarzewski M
    Dev Period Med; 2015; 19(1):16-24. PubMed ID: 26003066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving the Sensitivity and Positive Predictive Value in a Cystic Fibrosis Newborn Screening Program Using a Repeat Immunoreactive Trypsinogen and Genetic Analysis.
    Sontag MK; Lee R; Wright D; Freedenberg D; Sagel SD
    J Pediatr; 2016 Aug; 175():150-158.e1. PubMed ID: 27131402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cystic fibrosis screen positive inconclusive diagnosis (CFSPID): Experience in Tuscany, Italy.
    Terlizzi V; Mergni G; Buzzetti R; Centrone C; Zavataro L; Braggion C
    J Cyst Fibros; 2019 Jul; 18(4):484-490. PubMed ID: 31005549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of specificity and sensitivity of IRT/IRT protocol in the cystic fibrosis newborn screening program: 6-year experience of three tertiary centers.
    Ramasli Gursoy T; Asfuroglu P; Sismanlar Eyuboglu T; Aslan AT; Yilmaz AI; Unal G; Kibar BS; Pekcan S; Hangul M; Kose M; Budakoglu II; Acican D
    Eur J Pediatr; 2023 Mar; 182(3):1067-1076. PubMed ID: 36565324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Newborn blood spot screening for cystic fibrosis with a four-step screening strategy in the Netherlands.
    Dankert-Roelse JE; Bouva MJ; Jakobs BS; Janssens HM; de Winter-de Groot KM; Schönbeck Y; Gille JJP; Gulmans VAM; Verschoof-Puite RK; Schielen PCJI; Verkerk PH
    J Cyst Fibros; 2019 Jan; 18(1):54-63. PubMed ID: 30146269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cystic fibrosis newborn screening: outcome of infants with normal sweat tests.
    Edmondson C; Grime C; Prasad A; Cowlard J; Nwokoro CEC; Ruiz G; Wallis C; Balfour-Lynn IM
    Arch Dis Child; 2018 Aug; 103(8):753-756. PubMed ID: 29113966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of two different protocols of neonatal screening for cystic fibrosis.
    Narzi L; Lucarelli M; Lelli A; Grandoni F; Lo Cicero S; Ferraro A; Matarazzo P; Delaroche I; Quattrucci S; Strom R; Antonelli M
    Clin Genet; 2002 Sep; 62(3):245-9. PubMed ID: 12220442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Negative sweat test in hypertrypsinaemic infants with cystic fibrosis carrying rare CFTR mutations.
    Padoan R; Bassotti A; Seia M; Corbetta C
    Eur J Pediatr; 2002 Apr; 161(4):212-5. PubMed ID: 12014388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening for cystic fibrosis in newborn infants: results of a pilot programme based on a two tier protocol (IRT/DNA/IRT) in the Italian population.
    Corbetta C; Seia M; Bassotti A; Ambrosioni A; Giunta A; Padoan R
    J Med Screen; 2002; 9(2):60-3. PubMed ID: 12133923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gradual increase in sweat chloride concentration is associated with a higher risk of CRMS/CFSPID to CF reclassification.
    Salinas DB; Ginsburg DK; Wee CP; Saeed MM; Brewington JJ
    Pediatr Pulmonol; 2023 Apr; 58(4):1074-1084. PubMed ID: 36582049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective and parallel assessments of cystic fibrosis newborn screening protocols in the Czech Republic: IRT/DNA/IRT versus IRT/PAP and IRT/PAP/DNA.
    Krulišová V; Balaščaková M; Skalická V; Piskáčková T; Holubová A; Paděrová J; Křenková P; Dvořáková L; Zemková D; Kračmar P; Chovancová B; Vávrová V; Stambergová A; Votava F; Macek M
    Eur J Pediatr; 2012 Aug; 171(8):1223-9. PubMed ID: 22581207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cystic fibrosis newborn screening: the importance of bloodspot sample quality.
    Doull I; Course CW; Hanks RE; Southern KW; Forton JT; Thia LP; Moat SJ
    Arch Dis Child; 2021 Mar; 106(3):253-257. PubMed ID: 32859613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.